{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:17:22Z","timestamp":1787498242372,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Serpentine supravenous hyperpigmentation (SSH) describes increased skin pigmentation that develops in the area immediately overlying the vessels through which chemotherapeutic drugs are administered. While SSH can be cosmetically distressing and there are no definitive management options, the literature is severely limited and  the variations in clinical presentation, risk factors, and histopathology of SSH across patients are not well understood. We aimed to systematically summarize characteristics from current available data, and thus improve SSH awareness and management. A literature search was conducted in PubMed using specific eligibility criteria through the end of December 2022. Included articles focused on patients who experienced SSH after chemotherapy infusion. Study quality was assessed using a modified Oxford Centre for Evidence-Based Medicine quality rating scheme. Of the 41 articles identified by literature search, 24 met eligibility criteria. Two additional articles were identified through the reference sections of retrieved articles, for 26 articles total. All articles were case reports, representing 28 patients total. Locations of SSH were mostly in the forearm near the site of injection (85%), and the most common associated symptom was erythema. Histopathologic analysis was available for half of cases, the majority of which were inflammatory in nature. The most common inflammatory pattern observed was a vacuolar\/lichenoid interface dermatitis. Duration of SSH ranged from days to\u2009&gt;\u20091 year after the chemotherapy was stopped. Six (21%) patients were managed with topical steroids and oral vasodilators, six (21%) patients switched to central venous infusion rather than peripheral infusion, five (18%) patients received only supportive care, three (11%) patients received venous washing with chemotherapy, three (11%) patients stopped chemotherapy, and one (4%) patient reduced the chemotherapy dosage. Ten (36%) patients attained complete resolution, seven (25%) had SSH that was near resolution\/fading, and three (11%) had persistent hyperpigmentation. Although SSH often spontaneously resolves once the chemotherapeutic agent is stopped, it can persist in some patients and cause significant distress. As the literature is severely limited and there are no definitive treatments, additional research using more standardized definitions and methods of assessments is necessary to improve characterization of SSH and evaluate potential interventions.<\/jats:p>","DOI":"10.1007\/s00403-024-03057-2","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T11:02:49Z","timestamp":1716548569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review"],"prefix":"10.1007","volume":"316","author":[{"given":"Judy","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca C.","family":"Obiakor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony A.","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison S.","family":"Dobry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"40","key":"3057_CR1","first-page":"83","volume":"1","author":"S Narayan","year":"2022","unstructured":"Narayan S, Talwar V, Redhu P et al (2022) Serpentine supra-venous hyperpigmentation \u201cbadge of courage\u201d in fight against cancer: an brief review. Gulf J Oncolog 1(40):83\u201387","journal-title":"Gulf J Oncolog"},{"issue":"5","key":"3057_CR2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","volume":"77","author":"J Dai","year":"2017","unstructured":"Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME (2017) Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol 77(5):902-910.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.044","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"3057_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5070\/D309M643S1","volume":"17","author":"SK Ghosh","year":"2011","unstructured":"Ghosh SK, Bandyopadhyay D, Ghoshal L, Basu S (2011) Letter: Docetaxel-induced supravenous serpentine dermatitis. Dermatol Online J 17(11):16","journal-title":"Dermatol Online J"},{"issue":"4","key":"3057_CR4","doi-asserted-by":"publisher","first-page":"e12981","DOI":"10.1111\/dth.12981","volume":"32","author":"FT Akyurek","year":"2019","unstructured":"Akyurek FT, Sari N, Ugurluoglu C, Kurtipek GS (2019) Serpentine supravenous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: a case report. Dermatol Ther 32(4):e12981. https:\/\/doi.org\/10.1111\/dth.12981","journal-title":"Dermatol Ther"},{"issue":"3","key":"3057_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/SMJ.0b013e3181ce0f5e","volume":"103","author":"ER Geddes","year":"2010","unstructured":"Geddes ER, Cohen PR (2010) Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy. South Med J 103(3):231\u2013235. https:\/\/doi.org\/10.1097\/SMJ.0b013e3181ce0f5e","journal-title":"South Med J"},{"issue":"5 Pt 2","key":"3057_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0190-9622(98)70361-5","volume":"39","author":"RM Pujol","year":"1998","unstructured":"Pujol RM, Rocamora V, Lopez-Pousa A, Taberner R, Alomar A (1998) Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 39(5 Pt 2):839\u2013842. https:\/\/doi.org\/10.1016\/s0190-9622(98)70361-5","journal-title":"J Am Acad Dermatol"},{"key":"3057_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-206793","author":"S Suvirya","year":"2014","unstructured":"Suvirya S, Agrawal A, Parihar A (2014) 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2014-206793","journal-title":"BMJ Case Rep"},{"issue":"2","key":"3057_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.1976.03270020012002","volume":"236","author":"WJ Hrushesky","year":"1976","unstructured":"Hrushesky WJ (1976) Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA 236(2):138","journal-title":"JAMA"},{"issue":"6","key":"3057_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.4103\/0378-6323.72459","volume":"76","author":"R Rao","year":"2010","unstructured":"Rao R, Balachandran C (2010) Serpentine supravenous pigmentation. A rare vasculo-cutaneous effect induced by systemic 5-fluorouracil. Indian J Dermatol Venereol Leprol 76(6):714\u2013715. https:\/\/doi.org\/10.4103\/0378-6323.72459","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"3057_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000247412","volume":"185","author":"KU Schallreuter","year":"1992","unstructured":"Schallreuter KU, Ring J (1992) A probable mechanism for hyperpigmentation by fotemustine. Dermatology 185(1):76\u201377. https:\/\/doi.org\/10.1159\/000247412","journal-title":"Dermatology"},{"issue":"4","key":"3057_CR11","first-page":"E20","volume":"99","author":"M Noori","year":"2017","unstructured":"Noori M, Hunter-Ellul L, Kelly B (2017) Serpentine supravenous hyperpigmentation following cisplatin and pemetrexed chemotherapy. Cutis 99(4):E20\u2013E22","journal-title":"Cutis"},{"issue":"3","key":"3057_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1468-3083.2005.01088.x","volume":"19","author":"I Aydogan","year":"2005","unstructured":"Aydogan I, Kavak A, Parlak AH, Alper M, Annakkaya AN, Erbas M (2005) Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol 19(3):345\u2013347. https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01088.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"3057_CR13","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/ccr3.1102","volume":"5","author":"I Jamalpur","year":"2017","unstructured":"Jamalpur I, Mogili HR, Koratala A (2017) Serpentine supravenous hyperpigmentation. Clin Case Rep 5(9):1546\u20131547. https:\/\/doi.org\/10.1002\/ccr3.1102","journal-title":"Clin Case Rep"},{"issue":"4","key":"3057_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000246423","volume":"192","author":"E Baselga","year":"1996","unstructured":"Baselga E, Drolet BA, Casper J, Esterly NB (1996) Chemotherapy-associated supravenous hyperpigmentation. Dermatology 192(4):384\u2013385. https:\/\/doi.org\/10.1159\/000246423","journal-title":"Dermatology"},{"issue":"6","key":"3057_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/j.1365-2133.2005.06633.x","volume":"152","author":"GY Chen","year":"2005","unstructured":"Chen GY, Lee JY, Chen WC (2005) Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma. Br J Dermatol 152(6):1383\u20131385. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06633.x","journal-title":"Br J Dermatol"},{"issue":"1","key":"3057_CR16","first-page":"1","volume":"12","author":"G Lancman","year":"2018","unstructured":"Lancman G, Steinberg A, Gabrilove J (2018) Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL. Int J Hematol Oncol Stem Cell Res 12(1):1\u20133","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"4","key":"3057_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4103\/0378-6323.156191","volume":"81","author":"A Das","year":"2015","unstructured":"Das A, Kumar D, Mohanty S, Mondal AK, Chowdhury SN, Bandyopadhyay D (2015) Serpentine supravenous hyperpigmentation induced by docetaxel. Indian J Dermatol Venereol Leprol 81(4):434. https:\/\/doi.org\/10.4103\/0378-6323.156191","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"3057_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1046\/j.1468-3083.2002.00424.x","volume":"16","author":"K Lang","year":"2002","unstructured":"Lang K, Groeger M, Neumann NJ, Ruzicka T, Fritsch C (2002) Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin\u2019s disease. J Eur Acad Dermatol Venereol 16(2):162\u2013163. https:\/\/doi.org\/10.1046\/j.1468-3083.2002.00424.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3057_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/tbj.12405","volume":"21","author":"EC Roach","year":"2015","unstructured":"Roach EC, Petekkaya I, Gezgen G, \u00dcnl\u00fc O, Altundag K (2015) Serpentine supravenous hyperpigmentation resulting from vinorelbine administration. Breast J 21(3):311\u2013312. https:\/\/doi.org\/10.1111\/tbj.12405","journal-title":"Breast J"},{"issue":"3","key":"3057_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000247152","volume":"188","author":"R Cecchi","year":"1994","unstructured":"Cecchi R, Tuci F, Giomi A, Innocenti F (1994) Supravenous hyperpigmentation induced by vinorelbine. Dermatology 188(3):244. https:\/\/doi.org\/10.1159\/000247152","journal-title":"Dermatology"},{"issue":"3","key":"3057_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1067\/mjd.2000.106239","volume":"43","author":"D Marcoux","year":"2000","unstructured":"Marcoux D, Anex R, Russo P (2000) Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. J Am Acad Dermatol 43(3):540\u2013546. https:\/\/doi.org\/10.1067\/mjd.2000.106239","journal-title":"J Am Acad Dermatol"},{"key":"3057_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm0911228","author":"CC Chan","year":"2010","unstructured":"Chan CC, Lin SJ (2010) Images in clinical medicine Serpentine supravenous hyperpigmentation. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMicm0911228","journal-title":"N Engl J Med"},{"issue":"3","key":"3057_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jaad.2005.01.127","volume":"53","author":"V Jain","year":"2005","unstructured":"Jain V, Bhandary S, Prasad GN, Shenoi SD (2005) Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 53(3):529\u2013530. https:\/\/doi.org\/10.1016\/j.jaad.2005.01.127","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3057_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1046\/j.1365-2133.2000.03518.x","volume":"142","author":"D Schrijvers","year":"2000","unstructured":"Schrijvers D, Van Den Brande J, Vermorken JB (2000) Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 142(5):1069\u20131070. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03518.x","journal-title":"Br J Dermatol"},{"issue":"25","key":"3057_CR25","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1056\/NEJMicm2207158","volume":"387","author":"NS Maalouf","year":"2022","unstructured":"Maalouf NS, Morand M (2022) Serpentine Supravenous Hyperpigmentation. N Engl J Med 387(25):e67. https:\/\/doi.org\/10.1056\/NEJMicm2207158","journal-title":"N Engl J Med"},{"issue":"4","key":"3057_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/j.1365-2133.2008.08438.x","volume":"158","author":"J Mataix","year":"2008","unstructured":"Mataix J, Betlloch I, Palmero F, Romero A (2008) Persistent supravenous eruption induced by intravenous bortezomib therapy. Br J Dermatol 158(4):863\u2013864. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08438.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"3057_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1590\/abd1806-4841.20153296","volume":"90","author":"A Fernandes Kde","year":"2015","unstructured":"Fernandes Kde A, Felix PA (2015) Persistent docetaxel-induced supravenous erythematous eruption. An Bras Dermatol 90(5):728\u2013730. https:\/\/doi.org\/10.1590\/abd1806-4841.20153296","journal-title":"An Bras Dermatol"},{"key":"3057_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70280-f","author":"SJ Vukelja","year":"1991","unstructured":"Vukelja SJ, Bonner MW, McCollough M et al (1991) Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/0190-9622(91)70280-f","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03057-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:30:30Z","timestamp":1719387030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03057-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03057-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"215"}}